Investor Relations

Latest Financial Results

Stock Information

Aurinia Pharmaceuticals Inc.
Nasdaq: AUPH Symbol
Price
Change
Volume
Day Range
52 Wk Range

Company Overview

Aurinia is a late clinical-stage biopharmaceutical company focused on developing and commercializing therapies to change the treatment paradigm for patients impacted by rare autoimmune and inflammatory conditions. Aurinia is advancing voclosporin as a potential best-in-class and first-in-class therapy for the treatment of lupus nephritis (LN) in the U.S. and EU. The company is also exploring voclosporin in other proteinuric kidney diseases, and is advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Aurinia is actively exploring opportunities to fully realize the untapped potential of novel therapies and create meaningful impact to meet patient needs.

view management team  view board of directors

Contact Information

Investor Relations

Glenn Schulman, PharmD, MPH
Senior Vice President, Corporate Communications and Investor Relations
IR@auriniapharma.com

Transfer Agent

Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
www.computershare.com